BACKGROUND: Fatigue is the most common and disabling symptom affecting quality of life (QOL) and daily function in patients who have completed treatment for acute myeloid leukemia (AML). Although trials in patients with various solid tumors have reported improved fatigue and QOL following exercise interventions, there have been no studies in AML patients post treatment. METHODS:Forty patients aged ≥ 40 years who had completed treatment for AML were enrolled in a 12-week randomized phase II exercise intervention to determine feasibility (recruitment, retention, and adherence), efficacy, and safety of the intervention. Patients assigned to the exercise group received an individualized, moderate-intensity, 12-week home-based exercise program with weekly telephone support from a certified exercise physiologist. QOL, fatigue, and fitness outcomes were measured at baseline, 6 weeks, and 12 weeks. Between-group differences in 12-week change scores were calculated using linear regression adjusting for age and baseline function. RESULTS:Recruitment and retention rates were 38% and 91%, respectively. Adherence was low at 28%. Analyses did not suggest statistically significant or clinically important benefits in QOL, fatigue, or physical fitness with the intervention. The level of adherence did not appear to impact outcomes. There were no adverse events. CONCLUSION: A home-based exercise program for post-treatment AML patients age 40 years or older can be safely delivered with reasonable recruitment and high retention. However, feasibility was hampered by low adherence. Further research and program modification are needed to better understand and overcome barriers to exercise delivery and adherence in AML survivors.
RCT Entities:
BACKGROUND:Fatigue is the most common and disabling symptom affecting quality of life (QOL) and daily function in patients who have completed treatment for acute myeloid leukemia (AML). Although trials in patients with various solid tumors have reported improved fatigue and QOL following exercise interventions, there have been no studies in AMLpatients post treatment. METHODS: Forty patients aged ≥ 40 years who had completed treatment for AML were enrolled in a 12-week randomized phase II exercise intervention to determine feasibility (recruitment, retention, and adherence), efficacy, and safety of the intervention. Patients assigned to the exercise group received an individualized, moderate-intensity, 12-week home-based exercise program with weekly telephone support from a certified exercise physiologist. QOL, fatigue, and fitness outcomes were measured at baseline, 6 weeks, and 12 weeks. Between-group differences in 12-week change scores were calculated using linear regression adjusting for age and baseline function. RESULTS: Recruitment and retention rates were 38% and 91%, respectively. Adherence was low at 28%. Analyses did not suggest statistically significant or clinically important benefits in QOL, fatigue, or physical fitness with the intervention. The level of adherence did not appear to impact outcomes. There were no adverse events. CONCLUSION: A home-based exercise program for post-treatment AMLpatients age 40 years or older can be safely delivered with reasonable recruitment and high retention. However, feasibility was hampered by low adherence. Further research and program modification are needed to better understand and overcome barriers to exercise delivery and adherence in AML survivors.
Authors: Joachim Wiskemann; Peter Dreger; Rainer Schwerdtfeger; Andrea Bondong; Gerhard Huber; Nikolaus Kleindienst; Cornelia M Ulrich; Martin Bohus Journal: Blood Date: 2010-12-29 Impact factor: 22.113
Authors: Andrea Schumacher; Dieter Wewers; Achim Heinecke; Cristina Sauerland; Olaf M Koch; Jürgen van de Loo; Thomas Büchner; Wolfgang E Berdel Journal: Leuk Res Date: 2002-04 Impact factor: 3.156
Authors: Shabbir M H Alibhai; Marc Leach; Vikas Gupta; George A Tomlinson; Joseph M Brandwein; Fernando Suarez Saiz; Mark D Minden Journal: Crit Rev Oncol Hematol Date: 2008-09-07 Impact factor: 6.312
Authors: Peter T Katzmarzyk; Arthur S Leon; Jack H Wilmore; James S Skinner; D C Rao; Tuomo Rankinen; Claude Bouchard Journal: Med Sci Sports Exerc Date: 2003-10 Impact factor: 5.411
Authors: Daniel Y T Fong; Judy W C Ho; Bryant P H Hui; Antoinette M Lee; Duncan J Macfarlane; Sharron S K Leung; Ester Cerin; Wynnie Y Y Chan; Ivy P F Leung; Sharon H S Lam; Aliki J Taylor; Kar-keung Cheng Journal: BMJ Date: 2012-01-30
Authors: Maria Queralt Salas; Eshetu G Atenafu; Ora Bascom; Leeann Wilson; Wilson Lam; Arjun Datt Law; Ivan Pasic; Dennis Dong Hwan Kim; Fotios V Michelis; Zeyad Al-Shaibani; Armin Gerbitz; Auro Viswabandya; Jeffrey Howard Lipton; Jonas Mattsson; Shabbir M H Alibhai; Rajat Kumar Journal: Bone Marrow Transplant Date: 2020-06-30 Impact factor: 5.483
Authors: Heidi D Klepin; Janet A Tooze; Timothy S Pardee; Leslie R Ellis; Dmitriy Berenzon; Shannon L Mihalko; Suzanne C Danhauer; Arati V Rao; Tanya M Wildes; Jeff D Williamson; Bayard L Powell; Stephen B Kritchevsky Journal: J Am Geriatr Soc Date: 2016-09-14 Impact factor: 5.562
Authors: Heidi D Klepin; Ellen Ritchie; Brittny Major-Elechi; Jennifer Le-Rademacher; Drew Seisler; Libby Storrick; Ben L Sanford; Guido Marcucci; Weiqiang Zhao; Susan A Geyer; Karla V Ballman; Bayard L Powell; Maria R Baer; Wendy Stock; Harvey Jay Cohen; Richard M Stone; Richard A Larson; Geoffrey L Uy Journal: J Geriatr Oncol Date: 2019-10-24 Impact factor: 3.599